Loading…
Loading…
CHEK (Check-Cap Ltd.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
CHEK does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CHEK and 80,000+ other tickers.
See exactly how CHEK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CHEK and 80,000+ other tickers.
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering, the C-Scan system, is composed of three integral parts: the C-Scan Cap, an ingestible X-ray scanning capsule for detecting suspected polyps; the C-Scan Track, a disposable unit that adheres to the…
Check-Cap (NASDAQ: CHEK - Get Free Report) and Accuray (NASDAQ: ARAY - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Profitability This table compares Check-Cap and Accuray's net margins,
Nasdaq-listed AI company gains overwhelming shareholder support for its transformational merger, positioning MBody AI ($CHEK) as a hardware-agnostic embodied intelligence leader ready to scale enterprise automation. Las Vegas, Nevada and Isfiya, Isreal--(Newsfile Corp. - November 17, 2025) - MBody AI Corp. ("MBody AI") and Check-Cap Ltd.
MBody AI ($CHEK) continues scaling its hardware-agnostic MBody AI Orchestrator(TM) platform across global enterprise deployments. Las Vegas, Nevada and Isfiya, Isreal--(Newsfile Corp. - November 10, 2025) - MBody AI, a market leader in embodied artificial intelligence, and Check-Cap Ltd.
Shareholders gain exclusive early access to a market-leading embodied AI company driving global growth, innovation, and long-term value creation. Isfiya, Israel--(Newsfile Corp. - November 6, 2025) - Check-Cap Ltd.
Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting TORONTO , May 14, 2025 /PRNewswire/ -- Apollo Technology Capital Corporation ("Apollo Capital"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs", or the "Company"), owning approximately 3.0% of the Company's common stock, today posed several critical questions that shareholders should ask MediPharm management on this morning's conference call following its first quarter 2025 earnings report. CEO David Pidduck and his management team have not held a call with shareholders since the second quarter of 2024 to avoid having to defend themselves after destroying 99% of the value of the company's stock, or nearly $1 billion.